Dianthus Therapeutics Price Target Raised to 56.00
DNTH Stock | 22.96 1.77 7.16% |
Under 61% of all Dianthus Therapeutics' traders are looking to take a long position. The analysis of the overall investor sentiment regarding Dianthus Therapeutics suggests that some traders are interested. Dianthus Therapeutics' investing sentiment shows overall attitude of investors towards Dianthus Therapeutics.
Dianthus |
Dianthus Therapeutics had its target price hoisted by research analysts at Raymond James from 51.00 to 56.00 in a report issued on Friday,Benzinga reports. The firm presently has an outperform rating on the stock. Raymond James price objective indicates a potential upside of 93.97 percent from the stocks previous close. Several
Read at thelincolnianonline.com
Dianthus Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Dianthus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Dianthus Therapeutics Fundamental Analysis
We analyze Dianthus Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dianthus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dianthus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Dianthus Therapeutics is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Dianthus Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dianthus Therapeutics stock to make a market-neutral strategy. Peer analysis of Dianthus Therapeutics could also be used in its relative valuation, which is a method of valuing Dianthus Therapeutics by comparing valuation metrics with similar companies.
Peers
Dianthus Therapeutics Related Equities
PSFE | Paysafe | 16.46 | ||||
CDR-PB | Cedar Realty | 4.81 | ||||
QTWO | Q2 Holdings | 2.54 | ||||
RXT | Rackspace Technology | 1.40 | ||||
VLGEA | Village Super | 1.32 | ||||
ONTF | ON24 | 0.57 | ||||
BILL | Bill | 0.70 |
Complementary Tools for Dianthus Stock analysis
When running Dianthus Therapeutics' price analysis, check to measure Dianthus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dianthus Therapeutics is operating at the current time. Most of Dianthus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dianthus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dianthus Therapeutics' price. Additionally, you may evaluate how the addition of Dianthus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |